• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于治疗应用的钬-乙二胺四甲叉膦酸（Ho-EDTMP）的生产、质量控制和药代动力学研究。

Production, quality control and pharmacokinetic studies of Ho-EDTMP for therapeutic applications.

作者信息

Bahrami-Samani Ali, Bagheri Reza, Jalilian Amir R, Shirvani-Arani Simindokht, Ghannadi-Maragheh Mohammad, Shamsaee Mojtaba

机构信息

Radiopharmaceutical Research and Development Lab (RRDL), Nuclear Science and Technology Research Institute (NSTRI), Tehran, Postal code: 14155-1339, Iran.

出版信息

Sci Pharm. 2010 Jul-Sep;78(3):423-33. doi: 10.3797/scipharm.1004-21. Epub 2010 Jun 9.

DOI:10.3797/scipharm.1004-21
PMID:21179355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3002809/
Abstract

(166)Ho-EDTMP is a major therapeutic agent which is widely used in bone palliation therapy. In this study, a (166)Ho-EDTMP complex was prepared successfully using an in-house synthesized EDTMP ligand and (166)HoCl(3). Ho-166 chloride was obtained by thermal neutron irradiation (1 Ã 10(13) ncm(â2)s(â1)) of natural Ho(NO(3))(3) samples (specific activity = 3â5 GBq/mg), dissolved in acidic media. The radiochemical purity of (166)Ho-EDTMP was checked by ITLC (>99%) and stability studies in presence of human serum and final preparation were performed. The biodistribution of (166)Ho-EDTMP and (166)HoCl(3) in wild-type rats was checked by scarification. SPECT imaging of (166)Ho-EDTMP was also performed in wild-type rats. A comparative accumulation study for (166)Ho-EDTMP and (166)HoCl(3) was performed for vital organs up to 48h. Significant bone accumulation (>70%) of the tracer in 48h was observed.

摘要

（166）钬-乙二胺四甲基膦酸是一种广泛用于骨姑息治疗的主要治疗剂。在本研究中，使用自行合成的乙二胺四甲基膦酸配体和（166）HoCl₃成功制备了（166）钬-乙二胺四甲基膦酸配合物。通过对天然Ho(NO₃)₃样品（比活度 = 3 - 5 GBq/mg）进行热中子辐照（1×10¹³ n/cm²·s）获得氯化钬-166，将其溶解在酸性介质中。通过薄层色谱法（>99%）检查（166）钬-乙二胺四甲基膦酸的放射化学纯度，并在人血清存在下进行稳定性研究及最终制剂的制备。通过放血法检查（166）钬-乙二胺四甲基膦酸和（166）HoCl₃在野生型大鼠体内的生物分布。还在野生型大鼠中进行了（166）钬-乙二胺四甲基膦酸的单光子发射计算机断层扫描成像。对（166）钬-乙二胺四甲基膦酸和（166）HoCl₃在重要器官中长达48小时的累积进行了比较研究。观察到48小时内示踪剂在骨中的显著累积（>70%）。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/dada42fc2f7a/scipharm.2010.78.423f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/fbd04fc41705/scipharm.2010.78.423f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/e4d349dd47e0/scipharm.2010.78.423f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/3241f221f29f/scipharm.2010.78.423f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/d8d1a4f43265/scipharm.2010.78.423f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/28fcfa255e60/scipharm.2010.78.423f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/a3c79508ac37/scipharm.2010.78.423f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/46914b7374f3/scipharm.2010.78.423f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/cfde97a5a3cd/scipharm.2010.78.423f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/29c4bd5a4502/scipharm.2010.78.423f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/f0f06d3bc6f7/scipharm.2010.78.423f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/dada42fc2f7a/scipharm.2010.78.423f11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/fbd04fc41705/scipharm.2010.78.423f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/e4d349dd47e0/scipharm.2010.78.423f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/3241f221f29f/scipharm.2010.78.423f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/d8d1a4f43265/scipharm.2010.78.423f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/28fcfa255e60/scipharm.2010.78.423f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/a3c79508ac37/scipharm.2010.78.423f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/46914b7374f3/scipharm.2010.78.423f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/cfde97a5a3cd/scipharm.2010.78.423f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/29c4bd5a4502/scipharm.2010.78.423f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/f0f06d3bc6f7/scipharm.2010.78.423f10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/396a/3002809/dada42fc2f7a/scipharm.2010.78.423f11.jpg

相似文献

1
Production, quality control and pharmacokinetic studies of Ho-EDTMP for therapeutic applications.用于治疗应用的钬-乙二胺四甲叉膦酸（Ho-EDTMP）的生产、质量控制和药代动力学研究。
Sci Pharm. 2010 Jul-Sep;78(3):423-33. doi: 10.3797/scipharm.1004-21. Epub 2010 Jun 9.
2
Production, Quality Control and Pharmacokinetic Studies of (177)Lu-EDTMP for Human Bone Pain Palliation Therapy Trials.用于人类骨痛缓解治疗试验的（177）镥-乙二胺四甲叉膦酸的生产、质量控制及药代动力学研究
Iran J Pharm Res. 2012 Winter;11(1):137-44.
3
Production, Quality Control and Biological Evaluation of (166)Ho-PDTMP as a Possible Bone Palliation Agent.（166）Ho-PDTMP 作为一种可能的骨姑息治疗剂的制备、质量控制和生物学评价。
Iran J Basic Med Sci. 2013 May;16(5):719-25.
4
Development of (166)Holmium-1,2 Propylene Di-amino Tetra (Methy1enephosphonicacid) as a Possible Bone Palliation Agent.（166）钬-1,2-丙二胺四（亚甲基膦酸）作为一种可能的骨姑息治疗剂的研发。
World J Nucl Med. 2014 Jan;13(1):28-33. doi: 10.4103/1450-1147.138571.
5
(170)Tm-EDTMP: a potential cost-effective alternative to (89)SrCl(2) for bone pain palliation.（170）铥-乙二胺四甲撑膦酸：一种在缓解骨痛方面可能比（89）氯化锶更具成本效益的替代物。
Nucl Med Biol. 2009 Jul;36(5):561-8. doi: 10.1016/j.nucmedbio.2009.02.002. Epub 2009 May 7.
6
Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.适用于制备177Lu-EDTMP的自制冻干EDTMP试剂盒的配方、临床前评估及初步临床研究
Cancer Biother Radiopharm. 2014 Dec;29(10):412-21. doi: 10.1089/cbr.2014.1664.
7
Development of (166)Ho-phytate Complex for Radiosynovectomy.用于放射性滑膜切除的（166）钬-植酸盐复合物的研发
Nucl Med Mol Imaging. 2011 Jun;45(2):87-92. doi: 10.1007/s13139-010-0048-6. Epub 2011 Feb 17.
8
Preparation of (166)Dy/(166)Ho-EDTMP: a potential in vivo generator system for bone marrow ablation.（166）镝/（166）钬-乙二胺四甲基膦酸的制备：一种用于骨髓消融的潜在体内发生器系统
Nucl Med Commun. 2004 Jun;25(6):615-21. doi: 10.1097/01.mnm.0000126516.57329.07.
9
177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis.177镥-乙二胺四甲基膦酸：一种治疗骨转移引起骨痛的可行姑息治疗药物。
Cancer Biother Radiopharm. 2008 Apr;23(2):202-13. doi: 10.1089/cbr.2007.374.
10
Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical.EDTMP 的合成及即用试剂盒配方，用于制备 177Lu-EDTMP 作为骨缓解放射性药物。
Curr Radiopharm. 2023;16(1):38-43. doi: 10.2174/1874471015666220721095938.

引用本文的文献

1
Dy/Ho-labeled porous hydroxyapatite microparticles for treatment of inflammatory joint diseases - Exploring the advantages of in vivo generator.镝/钬标记的多孔羟基磷灰石微粒用于治疗炎性关节疾病——探索体内发生器的优势
Sci Rep. 2025 May 20;15(1):17480. doi: 10.1038/s41598-025-02373-5.
2
Animal-based radiation absorbed dose evaluation of holmium-166 labeled hydroxyapatite particulates in liver malignancies.基于动物的166钬标记羟基磷灰石微粒在肝脏恶性肿瘤中的辐射吸收剂量评估。
Asia Ocean J Nucl Med Biol. 2025;13(1):94-101. doi: 10.22038/aojnmb.2024.79679.1560.
3
Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics.

本文引用的文献

1
Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent.多物种动物研究 177Lu-EDTMP 的生物分布、药代动力学和毒性，这是一种有潜力的骨痛缓解药物。
Nucl Med Biol. 2010 Feb;37(2):215-26. doi: 10.1016/j.nucmedbio.2009.09.004. Epub 2009 Nov 12.
2
Determination of human absorbed dose of 67GA-DTPA-ACTH based on distribution data in rats.基于大鼠体内分布数据测定人67Ga-DTPA-促肾上腺皮质激素的吸收剂量
Radiat Prot Dosimetry. 2009 Jun;134(2):79-86. doi: 10.1093/rpd/ncp085.
3
166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
用于癌症治疗的放射性核素和放射性标记肽的进展
Pharmaceutics. 2023 Mar 17;15(3):971. doi: 10.3390/pharmaceutics15030971.
4
Cutting edge rare earth radiometals: prospects for cancer theranostics.前沿稀土放射性金属：癌症诊疗一体化的前景
EJNMMI Radiopharm Chem. 2022 Aug 26;7(1):21. doi: 10.1186/s41181-022-00173-0.
5
The various therapeutic applications of the medical isotope holmium-166: a narrative review.医用同位素钬-166的各种治疗应用：一项叙述性综述。
EJNMMI Radiopharm Chem. 2019 Aug 5;4(1):19. doi: 10.1186/s41181-019-0066-3.
6
Estimation of human absorbed dose for (166)Ho-PAM: comparison with (166)Ho-DOTMP and (166)Ho-TTHMP.（166）Ho-PAM对人体吸收剂量的估算：与（166）Ho-DOTMP和（166）Ho-TTHMP的比较。
Br J Radiol. 2016 Oct;89(1066):20160153. doi: 10.1259/bjr.20160153. Epub 2016 Aug 15.
7
Development of (166)Holmium-1,2 Propylene Di-amino Tetra (Methy1enephosphonicacid) as a Possible Bone Palliation Agent.（166）钬-1,2-丙二胺四（亚甲基膦酸）作为一种可能的骨姑息治疗剂的研发。
World J Nucl Med. 2014 Jan;13(1):28-33. doi: 10.4103/1450-1147.138571.
8
Production, Quality Control and Biological Evaluation of (166)Ho-PDTMP as a Possible Bone Palliation Agent.（166）Ho-PDTMP 作为一种可能的骨姑息治疗剂的制备、质量控制和生物学评价。
Iran J Basic Med Sci. 2013 May;16(5):719-25.
用于骨骼靶向放射治疗的166Ho-DOTMP辐射吸收剂量估计
J Nucl Med. 2006 Mar;47(3):534-42.
4
Therapy of metastatic bone pain.转移性骨痛的治疗。
J Nucl Med. 2001 Jun;42(6):895-906.
5
Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial.使用钐-153 来昔膦酸治疗转移性骨癌相关疼痛：一项双盲安慰剂对照临床试验
J Clin Oncol. 1998 Apr;16(4):1574-81. doi: 10.1200/JCO.1998.16.4.1574.
6
Samarium-153-EDTMP biodistribution and dosimetry estimation.钐-153-乙二胺四甲基膦酸的生物分布及剂量学估算。
J Nucl Med. 1993 Jul;34(7):1031-6.
7
Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases.钐-153-乙二胺四甲叉膦酸用于治疗骨转移引起的骨痛的剂量学和毒性研究。
J Nucl Med. 1994 Jan;35(1):63-9.
8
The management of intractable bone pain: a clinician's perspective.难治性骨痛的管理：临床医生视角
Semin Nucl Med. 1992 Jan;22(1):3-10. doi: 10.1016/s0001-2998(05)80151-5.
9
Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP.使用氨基膦酸共轭物166Ho-EDTMP在骨髓移植前进行特定的骨髓消融。
Blood. 1992 Sep 15;80(6):1608-13.